Story · Medicine & Biotech
Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion
1 outlet · first reported by WSJ Health on
Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases. (WSJ Health)
Coverage, in order
-
Johnson & Johnson to Buy Ollin Biosciences for $2.2 Billion
Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases.
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.